Skip to main content
Log in

The Economic Burden of Inappropriate Drug Prescribing, Lack of Adherence and Compliance, Adverse Drug Events in Older People

A Systematic Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Adverse drug events (ADEs) are an increasingly relevant issue for healthcare systems as they are associated with poorer health outcomes and avoidable misuse of resources. The rates of ADEs are higher in the elderly population, as many older patients have comorbidities, multiple drug prescriptions and deteriorated physical and cognitive functioning. The occurrence of ADEs can lead to a perceived lack of therapy efficacy and further underuse or suboptimal adherence in elderly people, with detrimental clinical outcomes. The present article systematically reviews the studies evaluating the economic impact of ADEs occurring as consequence of poor therapy adherence, inappropriate drug use, underuse of effective treatments and poor adherence, medication errors, drug-drug and drug-disease interactions.

A Medline systematic literature review of studies evaluating the economic consequences of inappropriate drug prescribing, lack of adherence and compliance, ADEs in older people was performed. English-language articles were screened through a three-step approach (title review, abstract review, full article review) to select pertinent studies quantitatively evaluating costs. We systematically reviewed evidence from767 articles. After title, abstract and full text review, 21 articles were found to measure economic implications ofADEs, inappropriate drug prescribing and poor adherence in elderly patients. Studies suggested that the economic impact of these undesired effects is substantial: hospital costs were the main cost driver, with a relevant part of them being preventable (consequences of inappropriate prescribing). Healthcare costs for unused drug wastage and destruction were also surprisingly high.

Although economic evidence in elderly patients is still limited, all studies seemed to confirm that the financial burden due to pharmacological treatment issues is relevant in elderly people. Including economic effects of adverse events in pharmacoeconomic analysis would be beneficial to improve the reliability of results. Preliminary evidence suggests that programmes aimed at comprehensively assessing geriatric conditions, detecting ‘high-risk’ prescriptions and training patients to comply with prescribed therapies could be costeffective measures to reduce the burden of ADEs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008 Feb 7; 451 (7179): 716–19

    Article  PubMed  CAS  Google Scholar 

  2. Crimmins EM, Hayward MD, Hagedorn A, et al. Change in disability-free life expectancy for Americans 70 years old and older. Demography 2009 Aug; 46 (3): 627–46

    Article  PubMed  Google Scholar 

  3. Chernew ME, Hirth RA, Cutler DM. Increased spending on health care: long-term implications for the nation. Health Aff (Millwood) 2009 Sep–Oct; 28 (5): 1253–5

    Article  Google Scholar 

  4. Bech M, Christiansen T, Khoman E, et al. Ageing and health care expenditure in EU-15. Eur J Health Econ 2011 Oct; 12 (5): 469–78

    Article  PubMed  Google Scholar 

  5. Herwartz H, Theilen B. The determinants of health-care expenditure: new results from semiparametric estimation. Health Econ 2010 Aug; 19 (8): 964–78

    Article  PubMed  Google Scholar 

  6. Dormont B, Grignon M, Huber H. Health expenditure growth: reassessing the threat of ageing. Health Econ 2006 Sep; 15 (9): 947–63

    Article  Google Scholar 

  7. Fernández-Olano C, Hidalgo JD, Cerdá-Díaz R, et al. Factors associated with health care utilization by the elderly in a public health care system. Health Policy 2006 Jan; 75 (2): 131–9

    Article  PubMed  Google Scholar 

  8. Saver BG, Doescher MP, Jackson JE, et al. Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health 2004 Mar–Apr; 7 (2): 133–43

    Article  PubMed  Google Scholar 

  9. Johnell K, Fastbom J, Rosén M, et al. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 2007 Jul; 41 (7): 1243–8

    Article  PubMed  Google Scholar 

  10. Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One 2012; 7 (8): e43617

    Article  PubMed  CAS  Google Scholar 

  11. Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 2009; 26 (2): 145–55

    Article  PubMed  Google Scholar 

  12. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 Jul 24–31; 288 (4): 462–7

    Article  PubMed  Google Scholar 

  13. Fialová D, Onder G. Medication errors in elderly people: contributing factors and future perspectives. Br J Clin Pharmacol 2009 June; 67 (6): 641–5

    Article  PubMed  Google Scholar 

  14. Zakharov S, Tomas N, Pelclova D. Medication errors-an enduring problem for children and elderly patients. Ups J Med Sci 2012 Aug; 117 (3): 309–17

    Article  PubMed  Google Scholar 

  15. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600 000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007; 30 (10): 911–18

    Article  PubMed  Google Scholar 

  16. Bacic-Vrca V, Marusic S, Erdeljic V, et al. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 2010 Dec; 32 (6): 815–21

    Article  PubMed  CAS  Google Scholar 

  17. Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int 2012 Oct; 12 (4): 761–2

    Article  PubMed  Google Scholar 

  18. Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med 2012 May; 28 (2): 273–86

    Article  PubMed  Google Scholar 

  19. Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008 Feb; 64 (2): 183–99

    Article  PubMed  Google Scholar 

  20. Corsonello A, Pedone C, Corica F, et al., Gruppo Italiano di Farmacovigilanza nell-Anziano (GIFA) Investigators. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165 (7): 790–5

    Article  PubMed  Google Scholar 

  21. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011 Nov 24; 365 (21): 2002–12

    Article  PubMed  CAS  Google Scholar 

  22. Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007 Dec 4; 147 (11): 755–65

    PubMed  Google Scholar 

  23. Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002 Jan–Feb; 11 (1): 65–72

    Article  PubMed  Google Scholar 

  24. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003 Mar 5; 289 (9): 1107–16

    Article  PubMed  Google Scholar 

  25. Swedish National Institute of Public Health (SNIPH) (2007), Healthy Ageing: a Challenge for Europe, Brussels [Stockholm], http://www.healthyageing.nu

    Google Scholar 

  26. Fick DM, Mion LC, Beers MH, et al. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health 2008 Feb; 31 (1): 42–51

    Article  PubMed  Google Scholar 

  27. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004; 21 (12): 793–811

    Article  PubMed  Google Scholar 

  28. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007 Sep 19; 9 (3): 58

    PubMed  Google Scholar 

  29. Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metaanalysis. Osteoporos Int 2010 Nov; 21 (11): 1943–51

    Article  PubMed  CAS  Google Scholar 

  30. Kusserow RP. Medication Regimens: Causes of Noncompliance. Washington, DC: Office of Inspector General, U.S. Department of Health and Human Services; 1990. WOEI-04-89-8912

    Google Scholar 

  31. Sullivan SD, Krelig DH, Hazlet TK. Noncompliance with medical regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990; 2: 19–33

    Google Scholar 

  32. Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001 Oct; 10 (7): 601–15

    Article  PubMed  CAS  Google Scholar 

  33. Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19 (12): 1185–97

    Article  PubMed  CAS  Google Scholar 

  34. Kale A, Keohane CA, Maviglia S, et al. Adverse drug events caused by serious medication administration errors. BMJ Qual Saf 2012 Nov; 21 (11): 933–8

    Article  PubMed  Google Scholar 

  35. Klopotowska JE, Wierenga PC, Smorenburg SM, et al.; on behalf of the WINGS study group. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol 2012 Jun 7 [Epub ahead of print]

    Google Scholar 

  36. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009 Oct; 62(10): e1–34

    Article  PubMed  Google Scholar 

  37. Pérez Menéndez-Conde C, Bermejo Vicedo T, Delgado Silveira E, et al. Adverse drug reactions which provoke hospital admission. Farm Hosp 2011 Sep–Oct; 35 (5): 236–43

    Article  PubMed  Google Scholar 

  38. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010 Sep; 16 (9): e228–34

    PubMed  Google Scholar 

  39. Hoonhout LH, de Bruijne MC, Wagner C, et al. Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf 2010 Oct 1; 33 (10): 853–64

    Article  PubMed  Google Scholar 

  40. Manson SC, Benedict A, Pan F, et al. Potential economic impact of increasing low dose aspirin usage on CVD in the USA. Curr Med Res Opin 2010 Oct; 26 (10): 2365–73

    Article  PubMed  Google Scholar 

  41. Doggrell SA. Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging 2010 Mar 1; 27 (3): 239–54

    Article  PubMed  Google Scholar 

  42. Pratt N, Roughead EE, Ryan P, et al. Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study. Drugs Aging 2010 Jan 1; 27 (1): 63–71

    Article  PubMed  CAS  Google Scholar 

  43. Broyles RW, Chou AF, Mattachione S, et al. The effect of adverse medical events on spending on inpatient care. Qual Manag Health Care 2009 Oct–Dec; 18 (4): 315–25

    PubMed  Google Scholar 

  44. Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol 2010 Feb; 24 (1): 9–17

    Article  PubMed  CAS  Google Scholar 

  45. Ryan C, O’Mahony D, Kennedy J, et al. Appropriate prescribing in the elderly: an investigation of two screening tools, Beers criteria considering diagnosis and independent of diagnosis and improved prescribing in the elderly tool to identify inappropriate use of medicines in the elderly in primary care in Ireland. J Clin Pharm Ther 2009 Aug; 34 (4): 369–76

    Article  PubMed  CAS  Google Scholar 

  46. Chapman RH, Petrilla AA, Benner JS, et al. Predictors of adherence to concomitant antihypertensive and lipidlowering medications in older adults: a retrospective, cohort study. Drugs Aging 2008; 25 (10): 885–92

    Article  PubMed  Google Scholar 

  47. van der Velde N, Meerding WJ, Looman CW, et al. Cost effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 2008; 25 (6): 521–9

    Article  PubMed  Google Scholar 

  48. Krupski TL, Foley KA, Baser O, et al. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007 Oct; 178 (4 Pt 1): 1423–8

    Article  PubMed  Google Scholar 

  49. Rocchiccioli JT, Sanford J, Caplinger B. Polymedicine and aging. Enhancing older adult care through advanced practitioners. GNPs and elder care pharmacists can help provide optimal pharmaceutical care. J Gerontol Nurs 2007 Jul; 33 (7): 19–24

    PubMed  Google Scholar 

  50. Tinetti ME, Gordon C, Sogolow E, et al. Fall-risk evaluation and management: challenges in adopting geriatric care practices. Gerontologist 2006 Dec; 46 (6): 717–25

    Article  PubMed  Google Scholar 

  51. Nickel JC. BPH: costs and treatment outcomes. Am J Manag Care 2006 Apr; 12 (5 Suppl.): S141–8

    PubMed  Google Scholar 

  52. Fuhlbrigge AL, Bae SJ, Weiss ST, et al. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J Allergy Clin Immunol 2006 Feb; 117 (2): 359–66

    Article  PubMed  CAS  Google Scholar 

  53. Morant SV, McMahon AD, Cleland JG, et al. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004 Feb; 57 (2): 188–98

    Google Scholar 

  54. Solomon DH, Glynn RJ, Bohn R, et al. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol 2003 Apr; 30 (4): 792–8

    PubMed  Google Scholar 

  55. von Gunten V, Reymond JP, Boubaker K, et al. Antibiotic use: is appropriateness expensive? J Hosp Infect 2009 Feb; 71 (2): 108–11

    Article  Google Scholar 

  56. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf 2012 Sep 1; 35 (9): 769–81

    PubMed  Google Scholar 

  57. Field TS, Gilman BH, Subramanian S, et al. The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 2005 Dec; 43 (12): 1171–6

    Article  PubMed  Google Scholar 

  58. Anderson WK, Wahler R. Forum. Pharmacy management can reduce Medicare — and human costs. Aging today 2001; 22 (1): 3–8

    Google Scholar 

  59. Campbell NL, Boustani MA, Skopelja EN, et al. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother 2012 Jun; 10 (3): 165–77

    Article  PubMed  Google Scholar 

  60. Sengstock D, Vaitkevicius P, Salama A, et al. Underprescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence. Drugs Aging 2012 Feb 1; 29 (2): 93–103

    Article  PubMed  Google Scholar 

  61. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medicine adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003; 25: 2958–71

    Article  PubMed  Google Scholar 

  62. Balkrishnan R, Bhosle MJ, Camacho FT, et al. Predictors of medicine adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 2006; 175: 1067–71

    Article  PubMed  Google Scholar 

  63. Isacson D, Olofsson C. Drugs up in smoke: a study of caseated drugs in Sweden. Pharm World Sci 1999; 21: 96–9

    Article  PubMed  CAS  Google Scholar 

  64. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: how well are States closing the gap? Health Aff (Millwood) 2002 Jul–Dec; Suppl Web Exclusives: W253–68

    Google Scholar 

  65. Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011 May 1; 117 (9): 1917–27

    Article  PubMed  Google Scholar 

  66. Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extendedrelease capsules: review of postmarketing adverse events during the first year. J Opioid Manag 2012 Mar–Apr; 8 (2): 115–25

    Article  PubMed  Google Scholar 

  67. Brajovic S, Piazza-Hepp T, Swartz L, et al. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration. Pharmacoepidemiol Drug Saf 2012 Jun; 21 (6): 565–70; discussion 571–2

    Article  PubMed  Google Scholar 

  68. Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, et al. Comparing adverse event rates of oral blood glucoselowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011. Drug Saf 2011 Dec 1; 34 (12): 1191–202

    Article  PubMed  CAS  Google Scholar 

  69. World Health Organization 2002. The Importance of Pharmacovigilance. Safety monitoring of medicinal products. Available at URL: http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf [Accessed August 23, 2012]

    Google Scholar 

  70. Suh DC, Woodall BS, Shin SK, et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000 Dec; 34 (12): 1373–9

    Article  PubMed  CAS  Google Scholar 

  71. White TJ, Arakelian A, Rho JP. Counting the costs of drugrelated adverse events. Pharmacoeconomics 1999 May; 15 (5): 445–58

    Article  PubMed  CAS  Google Scholar 

  72. Crome P, Lally F, Cherubini A, et al. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging 2011 Aug 1; 28 (8): 667–77

    Article  PubMed  Google Scholar 

  73. Smith SR, Rublein JC, Marcus C, et al. A medication selfmanagement program to improve adherence to HIV therapy regimens. Patient Educ Couns 2003 Jun; 50 (2): 187–99

    Article  PubMed  Google Scholar 

  74. Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin- based therapy. Am J Manag Care 2012 Apr; 18 (3 Suppl.): S55–61

    PubMed  Google Scholar 

  75. American Pharmacists Association; National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). 2008. Available at url: http://www.accp.com/docs/positions/misc/CoreElements.pdf. [Accessed August 23, 2012]

    Google Scholar 

  76. Gonzalez J, Noga M. Medication therapy management. J Manag Care Pharm 2008; 14 (6 Suppl. S-c): S8–11

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Silvia Bustacchini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiatti, C., Bustacchini, S., Furneri, G. et al. The Economic Burden of Inappropriate Drug Prescribing, Lack of Adherence and Compliance, Adverse Drug Events in Older People. Drug Saf 35 (Suppl 1), 73–87 (2012). https://doi.org/10.1007/BF03319105

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03319105

Keywords

Navigation